Investors Lose Faith in AI Stocks U.S. Healthcare Sector Emerges as a Winner

Market Analysis

As the euphoria around artificial intelligence shows signs of fracturing, a notable rotation is under way on U.S. markets: investors are increasingly turning away from high-flying AI names and repositioning into the relative safety of the healthcare sector. The shift, reported by the Wall Street Journal, reflects demand for more stable earnings streams after a period of sky-high valuations in technology and AI-related stocks.

The Health Care Select Sector SPDR ETF (XLV) has been at the center of this move. After trading at a roughly 25% discount to the S&P 500 a year ago, the valuation gap has closed, and XLV now trades at about 19.3 times forward earnings slightly above the broader U.S. market. That repricing helped the healthcare sector rise about 2.4% in the S&P 500 on Tuesday, making it one of the days top performers.

Historical parallels add context. In the run-up to the 2008 financial crisis, healthcare stocks held up better than many cyclical sectors as rising rates and doubts about the housing boom created market stress. When the housing bubble burst, healthcare also fell but outperformed the overall market and delivered stronger returns over the following decade. Some strategists see similar defensive characteristics supporting the sector today, especially if technology-driven growth stalls.

Analysts at large banks point to several favorable drivers: ongoing medical innovation, a search for stability amid weakening confidence in other sectors, and easing political risks. Those factors, combined with lower macro sensitivity for many healthcare businesses, make the sector attractive to investors seeking resilience.

Stock Picks and Risks

Pharmaceutical giants Johnson & Johnson and Eli Lilly are among the most prominent beneficiaries of the rotation. Johnson & Johnson has forecast double-digit revenue growth into the back half of the decade, while Eli Lilly expects more than 30% revenue growth in 2026 thanks to strong sales of diabetes and weight-loss drugs such as Mounjaro and Zepbound. Together, Johnson & Johnson and Eli Lilly account for roughly a quarter of XLVs weight, underscoring their influence on the ETFs performance.

Medical device makers also feature in the watchlists of market observers. Stryker currently trades at about 18 times expected earnings, below its ten-year historical average price-to-earnings ratio of roughly 24. Abbott Laboratories and Zimmer Biomet are trading beneath their long-term valuation norms as well, which some investors find appealing from a mean-reversion perspective.

That said, not all corners of healthcare look equally attractive. Large insurers such as UnitedHealth and Humana continue to face margin pressure from elevated care costs and persistent political risk, which temper the sectors defensive appeal.

For investors, healthcare now presents an alternative to richly valued AI names. If the technology boom cools or enters a prolonged consolidation phase, pharmaceuticals and medtech companies especially those with durable revenue streams and clear growth catalysts could become long-term winners.

In short, the current market rotation reflects a classic balance-of-risk trade-off: investors are trading some upside potential in AI for steadier earnings and historically more stable returns in healthcare. Whether this reallocation proves prescient will depend on how persistent weakness in tech is, the pace of new drug and device approvals, and how insurers manage rising costs. For now, the healthcare sector looks like one of the safer harbors in an uncertain market environment.

Author: Paul Späthling, wallstreetONLINE editorial team.